Theravance Biopharma, Inc.
TBPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.54 | 0.55 | -0.02 | 0.11 |
| FCF Yield | -2.58% | -4.74% | -22.72% | -27.52% |
| EV / EBITDA | -12.27 | -14.80 | -7.91 | -5.36 |
| Quality | ||||
| ROIC | -17.84% | -17.38% | -15.71% | -77.21% |
| Gross Margin | 100.00% | 100.00% | -23.46% | 100.00% |
| Cash Conversion Ratio | 0.20 | 0.49 | 2.01 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.83% | 1.26% | -10.60% | -9.01% |
| Free Cash Flow Growth | 59.75% | 84.28% | 11.22% | 17.80% |
| Safety | ||||
| Net Debt / EBITDA | -0.31 | -0.23 | 2.94 | -2.27 |
| Interest Coverage | -18.44 | -23.84 | -14.44 | -30.16 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 41.90 | 0.00 |
| Cash Conversion Cycle | 388.01 | 111.07 | 119.08 | 380.10 |